<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Some patients with systemic <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> have concurrent <z:hpo ids='HP_0004377'>hematological neoplasms</z:hpo>, designated in the World Health Organization (WHO) classification as systemic <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> with associated clonal hematological non-mast cell lineage disease (<z:e sem="disease" ids="C1301365" disease_type="Neoplastic Process" abbrv="">SM-AHNMD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we analyzed 29 patients with <z:e sem="disease" ids="C1301365" disease_type="Neoplastic Process" abbrv="">SM-AHNMD</z:e> and compared them to 40 patients with pure SM </plain></SENT>
<SENT sid="2" pm="."><plain>The AHNMDs were classified as <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) (n = 10), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n = 7), myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (n = 4), B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo>/plasma cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (n = 7), and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (n = 1) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with <z:e sem="disease" ids="C1301365" disease_type="Neoplastic Process" abbrv="">SM-AHNMD</z:e> were older, more frequently had constitutional symptoms and <z:hpo ids='HP_0001871'>hematological abnormalities</z:hpo>, less often had <z:mp ids='MP_0001212'>skin lesions</z:mp>, and had an inferior overall survival compared with pure SM patients (48 months vs. not-reached, P &lt; 0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>Karyotypic abnormalities were detected in 9/28 (32%) patients with <z:e sem="disease" ids="C1301365" disease_type="Neoplastic Process" abbrv="">SM-AHNMD</z:e> but not in pure SM patients (P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Combined imaging/ fluorescence-in-situ hybridization performed in four <z:e sem="disease" ids="C1301365" disease_type="Neoplastic Process" abbrv="">SM-AHNMD</z:e> cases revealed shared abnormal signals in mast cells and myeloid cells in two patients with SM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and one patient with SM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but not in the mast cells of a case SM-associated with <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> with ATM-deletion </plain></SENT>
<SENT sid="6" pm="."><plain>Quantitative mutation analysis showed higher levels of mutant KIT D816V in SM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and SM-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> than in pure SM (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Our data indicate that the <z:e sem="disease" ids="C1301365" disease_type="Neoplastic Process" abbrv="">SM-AHNMD</z:e> category in the WHO classification is <z:hpo ids='HP_0001425'>heterogeneous</z:hpo>, including clonally related and unrelated forms of AHNMD </plain></SENT>
<SENT sid="8" pm="."><plain>The presentation, treatment, and outcome of patients with <z:e sem="disease" ids="C1301365" disease_type="Neoplastic Process" abbrv="">SM-AHNMD</z:e> is often dictated by the type of AHNMD </plain></SENT>
<SENT sid="9" pm="."><plain>Am </plain></SENT>
<SENT sid="10" pm="."><plain>J </plain></SENT>
<SENT sid="11" pm="."><plain>Hematol., 2013. Â© 2012 Wiley Periodicals, Inc </plain></SENT>
</text></document>